Clinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis.

Abstract : Fondaparinux (Arixtra((R))) is a synthetic, selective Factor Xa inhibitor. Its pharmacokinetic profile allows once-daily subcutaneous administration of the drug without any laboratory monitoring. The benefit-to-risk ratio of fondaparinux in the prevention of venous thromboembolism has been extensively studied in both surgical and acutely ill medical patients at risk of thrombosis. Its efficacy and safety have also been investigated in the initial treatment of symptomatic deep-vein thrombosis and pulmonary embolism. Finally, a number of Phase II trials investigated the safety and efficacy of fondaparinux in patients with acute coronary syndromes, and a large Phase III program is ongoing in this setting. This review focuses on the use of fondaparinux in the prevention and treatment of thromboembolic disorders.
Type de document :
Article dans une revue
Future Cardiology, Future Medicine, 2005, 1 (6), pp.743-58. 〈10.2217/14796678.1.6.743〉
Liste complète des métadonnées

https://hal-ujm.archives-ouvertes.fr/ujm-00440054
Contributeur : Patrick Mismetti <>
Soumis le : mercredi 9 décembre 2009 - 11:30:29
Dernière modification le : jeudi 11 janvier 2018 - 06:19:19

Identifiants

Citation

Hervé Decousus, Karine Rivron-Guillot, Gaelle Girard, Nathalie Moulin. Clinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis.. Future Cardiology, Future Medicine, 2005, 1 (6), pp.743-58. 〈10.2217/14796678.1.6.743〉. 〈ujm-00440054〉

Partager

Métriques

Consultations de la notice

150